Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Emergent Biosolutions (ER4) Stock Price & Analysis

2 Followers

ER4 Stock Chart & Stats

CHF 5.04CHF 0.24(4.89%)
At close: 5:30 PM GMT+1
No data to display
Day’s Range
CHF 5.04 - CHF 5.07
52-Week Range
CHF 3.58 - CHF 5.24
Previous Close
CHF 4.81
Volume
N/A
Average Volume (3M)
0
Market Cap
CHF 258.88M
Enterprise Value
CHF 675.38M
Total Cash (Recent Filing)
CHF 175.70M
Total Debt (Recent Filing)
CHF 507.70M
Price to Earnings (P/E)
―
Beta
-0.18
Next Earnings
Mar 03, 2027 (Est.)
EPS Estimate
-0.14
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Strong Cash Generation

Strong year-to-date EBITDA and operating cash flow provide internal funding for operations, debt service and selected growth initiatives. This improves resilience during uneven government delivery cycles, although the durability of cash conversion depends on improving underlying earnings quality.

Meaningful Debt Reduction

Substantial debt reduction and lower net leverage strengthen financial flexibility and reduce the burden of interest and refinancing obligations. A less leveraged balance sheet gives management more capacity to navigate volatile procurement timing while funding commercially important products.

Established Biodefense Government Position

The BioThrax award reinforces Emergent’s role as a supplier of mission-critical medical countermeasures to the U.S. government. Repeated preparedness procurement and a multiyear delivery schedule can support durable demand and strengthen the company’s strategic position in biodefense.

Bears Say

Declining Revenue And Delivery Dependence

Large year-over-year revenue declines and expected MCM contraction show that sales remain highly dependent on the timing of government and international deliveries. This creates uneven utilization and makes near-term operating performance less predictable even when contracts remain strategically valuable.

Renewed Operating Losses

Renewed operating and net losses indicate that gross profit is not currently sufficient to cover the company’s cost base and other charges. Persistent weak profitability could erode cash-generation quality, constrain reinvestment and make deleveraging harder if results do not stabilize.

Naloxone Pricing And Competitive Pressure

Competitive pricing and volume pressure in the commercial naloxone business threaten an important revenue stream and can weaken margins even with NARCAN’s market leadership. Continued funding challenges and new entrants may limit the segment’s ability to offset variable MCM sales.

Emergent Biosolutions News

ER4 FAQ

What was Emergent Biosolutions’s price range in the past 12 months?
Emergent Biosolutions lowest stock price was CHF3.58 and its highest was CHF5.24 in the past 12 months.
What is Emergent Biosolutions’s market cap?
Emergent Biosolutions’s market cap is CHF258.88M.
When is Emergent Biosolutions’s upcoming earnings report date?
Emergent Biosolutions’s next earnings report is estimated for Mar 03, 2027 (not yet confirmed), which is in 111 days.
How were Emergent Biosolutions’s earnings last quarter?
Emergent Biosolutions released its earnings results on Nov 02, 2026. The company reported -CHF0.297 earnings per share for the quarter, beating the consensus estimate of -CHF0.323 by CHF0.026.
Is Emergent Biosolutions overvalued?
According to Wall Street analysts Emergent Biosolutions’s price is currently Undervalued.
Does Emergent Biosolutions pay dividends?
Emergent Biosolutions does not currently pay dividends.
What is Emergent Biosolutions’s EPS estimate?
Emergent Biosolutions’s EPS estimate is -0.14.
How many shares outstanding does Emergent Biosolutions have?
Emergent Biosolutions has 51,415,180 shares outstanding.
What happened to Emergent Biosolutions’s price movement after its last earnings report?
Emergent Biosolutions reported an EPS of -CHF0.297 in its last earnings report, beating expectations of -CHF0.323. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Emergent Biosolutions?
Hedge funds hold Emergent Biosolutions shares: the largest hedge-fund position in Emergent Biosolutions is 759,451,663 shares, and hedge funds increased their holdings by 179.2K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology